The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.
J. A. Thompson
Research Funding - Seattle Genetics
A. Forero-Torres
Research Funding - Seattle Genetics
E. I. Heath
Research Funding - Seattle Genetics
S. M. Ansell
Research Funding - Seattle Genetics
S. K. Pal
Research Funding - Seattle Genetics
J. R. Infante
No relevant relationships to disclose
S. De Vos
Research Funding - Seattle Genetics
P. A. Hamlin
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
B. Zhao
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
K. Klussman
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
N. C. Whiting
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics